$25.49
0.271.07%
At close: Dec 15, 4:00 PM EST
$25.49
N/A
After Hours: 4:01 PM EST
Comments
Loading...
XOMA Royalty Insider Trading Activity
XOMANASDAQ
XOMA Royalty Insider Trading Activity | NASDAQ:XOMA | Benzinga
Track the latest XOMA Royalty insider trading activity. Stay informed on recent buys, sells, and market impact for XOMA Royalty stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are XOMA Royalty Corp Insiders Doing?
At XOMA Royalty Corp, recent insider activity has drawn attention. Over the last 30 days, insiders have report no sales in the last 30 days, meanwhile, insiders have reported buying a total of 100.00K shares for a total value of $2.51M.
Notable Recent Insider Buys and Sales
- On December 8, 2025, Owen Hughes, the company's CHIEF EXECUTIVE OFFICER purchased 100K shares for $25.05 each.
Ownership Statistics for XOMA Royalty Corp
Shares Outstanding
12.383M
Insider Shares Owned
1.251M
Insider Percentage Owned
10.3%
Institutional Shares Held
4.333M
Institutional Percentage Held
35.0%
| Dec 08, 2025 | Owen Hughes | CHIEF EXECUTIVE OFFICER | 100.00K | $25.05 | $2.50M | BUY | 4357.30% | 102.30K | Dec 04 | View |
| Sep 23, 2025 | Thomas M Burns | SVP, FINANCE & CFO | 7.52K | $35.99 | -$155.82K | SELL-OPTIONS | 30.60% | 32.08K | Sep 19 - Sep 22 | View |
| Jul 02, 2025 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 2.00K | $25.39 | $50.78K | BUY | 28.39% | 9.04K | Jun 30 | View |
| May 21, 2025 | Owen Hughes | CHIEF EXECUTIVE OFFICER | 27.72K | $25.38 | -$650.67K | SELL-OPTIONS | 74.97% | 64.70K | May 19 - May 20 | View |
| May 21, 2025 | Thomas M Burns | SVP, FINANCE & CFO | 7.29K | $25.38 | -$266.03K | SELL-OPTIONS | 42.21% | 24.56K | May 19 - May 20 | View |
| May 20, 2025 | BVF PARTNERS L PILBIOTECHNOLOGY VALUE FUND L PBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | 10% OWNER | -392.72K | $27.10 | -$10.64M | SELL | -23.65% | 1.27M | May 16 | View |
| Apr 09, 2025 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 2.00K | $24.70 | $49.40K | BUY | 39.64% | 7.04K | Apr 07 | View |
| Apr 07, 2025 | Joseph M Limber | — | 30.00K | $25.34 | $760.14K | BUY | ∞ | 16.21K | Apr 03 - Apr 07 | View |
| Apr 02, 2025 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 1.25K | $21.04 | $26.20K | BUY | 32.76% | 5.04K | Mar 31 | View |
| Apr 02, 2025 | Thomas M Burns | SVP, FINANCE & CFO | 1.00K | $25.46 | $25.46K | BUY | 33.33% | 4.00K | Apr 01 | View |
| Mar 25, 2025 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 4.13K | $23.89 | $98.75K | BUY | 620.72% | 4.80K | Mar 21 | View |
| Jan 28, 2025 | BVF PARTNERS L PILBIOTECHNOLOGY VALUE FUND L PBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | 10% OWNER | -650.72K | $26.10 | -$16.98M | SELL | -100.00% | 0.00 | Jan 24 | View |
| Jan 10, 2025 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 545.00 | $25.64 | $13.97K | BUY | 35.62% | 2.08K | Jan 08 | View |
| Jan 03, 2025 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 300.00 | $25.90 | $7.77K | BUY | 2.76% | 11.15K | Dec 31 | View |
| Nov 13, 2024 | Thomas M Burns | SVP, FINANCE & CFO | 8.00K | $29.94 | -$292.66K | SELL-OPTIONS | 93.49% | 16.55K | Nov 11 - Nov 13 | View |
| Nov 13, 2024 | Owen Hughes | CHIEF EXECUTIVE OFFICER | 31.48K | $29.95 | -$655.34K | SELL-OPTIONS | 572.35% | 36.98K | Nov 11 - Nov 13 | View |
| Oct 04, 2023 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 1.75K | $14.20 | $24.85K | BUY | 29.91% | 7.60K | Oct 02 - Oct 03 | View |
| Oct 04, 2023 | Owen Hughes | EXEC CHAIRMAN AND INTERIM CEO | 1.00K | $13.83 | $13.83K | BUY | 22.22% | 5.50K | Oct 02 | View |
| Sep 27, 2023 | Owen Hughes | EXEC CHAIRMAN AND INTERIM CEO | 2.50K | $14.43 | $36.08K | BUY | 125.00% | 4.50K | Sep 25 - Sep 26 | View |
| Jun 02, 2023 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 1.50K | $17.13 | $25.70K | BUY | 25.64% | 7.35K | May 31 | View |
| May 25, 2023 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 850.00 | $19.00 | $16.15K | BUY | 17.00% | 5.85K | May 23 | View |
| May 25, 2023 | Owen Hughes | INTERIM CEO | 2.00K | $23.63 | $47.26K | BUY | ∞ | 2.00K | May 23 - May 24 | View |
| May 22, 2023 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 1.00K | $19.50 | $19.50K | BUY | 25.00% | 5.00K | May 19 | View |
| May 17, 2023 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 500.00 | $23.20 | $11.60K | BUY | 14.29% | 4.00K | May 16 | View |
| May 16, 2023 | Bradley Sitko | CHIEF INVESTMENT OFFICER | 3.50K | $20.88 | $73.09K | BUY | ∞ | 1.50K | May 12 - May 15 | View |
| Jan 09, 2023 | BVF PARTNERS L PILBIOTECHNOLOGY VALUE FUND L PBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | DIRECTOR | 22.25K | $18.91 | $420.74K | BUY | 1.24% | 1.82M | Jan 05 - Jan 06 | View |
| Sep 27, 2022 | BVF PARTNERS L PILBIOTECHNOLOGY VALUE FUND L PBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | DIRECTOR | 24.64K | $16.61 | $409.31K | BUY | 1.39% | 1.80M | Sep 23 - Sep 27 | View |
| Sep 16, 2022 | BVF PARTNERS L PILBIOTECHNOLOGY VALUE FUND L PBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | DIRECTOR | 56.31K | $17.59 | $990.72K | BUY | 2.94% | 1.97M | Sep 14 - Sep 16 | View |
| Jul 18, 2022 | Thomas M Burns | SVP, FINANCE & CFO | 0.00 | $17.85 | -$55.26K | SELL-OPTIONS | 0.00% | 10.90K | Jul 15 | View |
| Jul 18, 2022 | James R Neal | CEO | 0.00 | $16.94 | -$645.35K | SELL-OPTIONS | 0.00% | 19.82K | Jul 15 | View |
| Mar 23, 2022 | James R Neal | CEO | 0.00 | $16.55 | -$1.34M | SELL-OPTIONS | 0.00% | 19.82K | Mar 21 - Mar 23 | View |
| Mar 23, 2022 | Thomas M Burns | SVP, FINANCE & CFO | 0.00 | $16.60 | -$364.66K | SELL-OPTIONS | 0.00% | 8.55K | Mar 21 - Mar 23 | View |
| Jun 29, 2021 | James R Neal | CEO | -9.03K | $33.62 | -$303.47K | SELL | -34.97% | 16.79K | Jun 25 | View |
| Apr 02, 2021 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | DIRECTOR | -651.70K | $38.36 | -$25.00M | SELL | -65.06% | 349.98K | Mar 31 | View |
| Dec 17, 2020 | James R Neal | — | 8.00K | $25.72 | -$732.00K | GRANT OR AWARD | 171.20% | 12.67K | Dec 15 | View |
| Dec 17, 2020 | Thomas M Burns | — | 2.00K | $23.95 | -$510.64K | GRANT OR AWARD | 54.30% | 5.68K | Dec 15 | View |
| Dec 15, 2020 | Matthew D Perry | — | 200.00K | $25.00 | $5.00M | PURCHASE | 1695.06% | 211.80K | Dec 11 | View |
| Dec 15, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 200.00K | $25.00 | $5.00M | PURCHASE | 1695.06% | 211.80K | Dec 11 | View |
| Nov 24, 2020 | James R Neal | — | 0.00 | $19.15 | -$546.18K | OPTION EXERCISE | 0.00% | 25.52K | Nov 20 - Nov 23 | View |
| Nov 24, 2020 | Thomas M Burns | — | 0.00 | $18.36 | -$343.95K | OPTION EXERCISE | 0.00% | 10.24K | Nov 20 - Nov 23 | View |
| Nov 06, 2020 | James R Neal | — | 0.00 | $15.76 | -$205.20K | OPTION EXERCISE | 0.00% | 25.52K | Nov 05 | View |
| Nov 06, 2020 | Thomas M Burns | — | 0.00 | $15.07 | -$176.67K | OPTION EXERCISE | 0.00% | 10.24K | Nov 05 | View |
| Sep 23, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 51.37K | $18.34 | $941.96K | PURCHASE | 3.00% | 1.76M | Sep 21 - Sep 23 | View |
| Sep 10, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 7.74K | $18.77 | $145.23K | PURCHASE | 0.45% | 1.74M | Sep 04 | View |
| Sep 01, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 35.62K | $18.71 | $666.48K | PURCHASE | 1.85% | 1.96M | Aug 28 - Sep 01 | View |
| Aug 25, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 28.18K | $19.40 | $546.65K | PURCHASE | 1.47% | 1.94M | Aug 21 - Aug 25 | View |
| Aug 20, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 6.16K | $19.47 | $120.00K | PURCHASE | 0.28% | 2.20M | Aug 18 - Aug 20 | View |
| Aug 14, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 27.02K | $18.46 | $498.74K | PURCHASE | 1.25% | 2.19M | Aug 12 - Aug 14 | View |
| Mar 27, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 8.26K | $17.20 | $142.13K | PURCHASE | 0.55% | 1.51M | Mar 25 | View |
| Mar 24, 2020 | James R Neal | — | 1.00K | $14.50 | $14.50K | PURCHASE | 4.08% | 25.52K | Mar 23 | View |
| Mar 23, 2020 | James R Neal | — | 1.00K | $16.41 | $16.41K | PURCHASE | 4.25% | 24.52K | Mar 20 | View |
| Mar 20, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 4.44K | $14.52 | $64.47K | PURCHASE | 0.30% | 1.50M | Mar 18 | View |
| Mar 17, 2020 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBVF I GP LLCBIOTECHNOLOGY VALUE FUND II LPBVF II GP LLCBiotechnology Value Trading Fund OS LPBVF Partners OS LtdBVF GP HOLDINGS LLCINCIL BVFMARK LAMPERT | — | 118.28K | $17.94 | $2.12M | PURCHASE | 8.57% | 1.50M | Mar 13 - Mar 17 | View |
| Dec 20, 2019 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 845.46K | $22.00 | $18.60M | BUY | 172.64% | 1.34M | Dec 18 - Dec 19 | View |
| Nov 08, 2019 | James R Neal | CEO | 0.00 | $13.75 | -$71.74K | SELL-OPTIONS | 0.00% | 21.87K | Nov 06 | View |
| Sep 20, 2019 | James R Neal | CHIEF EXECUTIVE OFFICER | 0.00 | $13.26 | -$242.84K | SELL-OPTIONS | 0.00% | 21.87K | Sep 18 - Sep 20 | View |
| Sep 20, 2019 | Thomas M Burns | SR. VP, FINANCE AND CFO | 0.00 | $12.85 | -$141.15K | SELL-OPTIONS | 0.00% | 8.95K | Sep 18 - Sep 19 | View |
| May 14, 2019 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 27.91K | $14.63 | $408.23K | BUY | 2.94% | 978.33K | May 10 - May 14 | View |
| May 14, 2019 | W. Denman Van Ness | DIRECTOR | -130.00 | $14.71 | -$1.91K | SELL | -1.29% | 9.94K | May 10 | View |
| Dec 19, 2018 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 25.00K | $14.19 | $354.79K | BUY | 2.70% | 950.42K | Dec 17 | View |
| Dec 13, 2018 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 36.46K | $14.46 | $527.24K | BUY | 4.10% | 925.42K | Dec 11 - Dec 13 | View |
| Dec 10, 2018 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 61.02K | $14.71 | $897.45K | BUY | 7.37% | 888.96K | Dec 06 - Dec 10 | View |
| Dec 04, 2018 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 9.80K | $14.91 | $146.14K | BUY | 1.20% | 827.93K | Nov 30 - Dec 04 | View |
| Nov 29, 2018 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 29.70K | $15.10 | $448.48K | BUY | 3.77% | 818.13K | Nov 27 - Nov 29 | View |
| Nov 21, 2018 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 72.25K | $14.17 | $1.02M | BUY | 10.09% | 788.43K | Nov 19 - Nov 21 | View |
| Nov 19, 2018 | PIL PARTNERS BVFFUND VALUE BIOTECHNOLOGYBIOTECHNOLOGY VALUE FUND II LPBiotechnology Value Trading Fund OS LPBVF Partners OS LtdINCIL BVFMARK LAMPERT | 10% OWNER | 31.99K | $13.48 | $431.35K | BUY | 4.68% | 716.18K | Nov 15 - Nov 16 | View |
| Nov 16, 2018 | W. Denman Van Ness | DIRECTOR | 2.17K | $9.76 | -$17.34K | SELL-OPTIONS | 30.45% | 9.27K | Nov 15 | View |
| Nov 15, 2018 | James R Neal | CEO | 4.00K | $13.26 | $53.06K | BUY | 20.73% | 23.29K | Nov 13 | View |
| Apr 27, 2018 | Thomas M Burns | SVP, FINANCE & CFO | 0.00 | $15.10 | -$211.31K | SELL-OPTIONS | 0.00% | 8.95K | Apr 26 - Apr 27 | View |
| Apr 27, 2018 | James R Neal | CEO | 0.00 | $15.01 | -$456.29K | SELL-OPTIONS | 0.00% | 19.29K | Apr 26 - Apr 27 | View |
| Nov 15, 2017 | James R Neal | CEO | 0.00 | $16.13 | -$1.12M | SELL-OPTIONS | 0.00% | 19.29K | Nov 13 - Nov 15 | View |
| Nov 15, 2017 | Thomas M Burns | SVP, FINANCE & CFO | 0.00 | $16.36 | -$547.90K | SELL-OPTIONS | 0.00% | 8.95K | Nov 13 - Nov 15 | View |
| May 18, 2017 | John Varian | DIRECTOR | -39.54K | $6.24 | -$246.92K | SELL | -86.83% | 6.00K | May 16 | View |
| Mar 23, 2017 | James R Neal | VP BUSINESS DEVELOPMENT | -5.11K | $5.40 | -$27.57K | SELL | -21.79% | 18.33K | Mar 21 | View |
| Mar 23, 2017 | Thomas M Burns | VP, FINANCE & CHIEF FINANCIAL | -2.60K | $5.40 | -$14.03K | SELL | -22.51% | 8.95K | Mar 21 | View |
| Feb 01, 2017 | James R Neal | VP BUSINESS DEVELOPMENT | -195.00 | $4.52 | -$880.50 | SELL | -0.91% | 21.13K | Feb 01 | View |
| Jan 10, 2017 | James R Neal | VP BUSINESS DEVELOPMENT | -125.00 | $5.15 | -$643.75 | SELL | -0.58% | 21.32K | Jan 09 | View |
| Dec 23, 2016 | John Varian | DIRECTOR | -13.55K | $5.75 | -$77.91K | SELL | -23.86% | 43.25K | Dec 21 | View |
| Dec 23, 2016 | Patrick J. Scannon | EXEC. VP & CSO | -3.23K | $5.75 | -$18.57K | SELL | -27.73% | 8.42K | Dec 21 | View |
| Nov 03, 2016 | James R Neal | VP BUSINESS DEVELOPMENT | -150.00 | $5.25 | -$787.50 | SELL | -0.70% | 21.20K | Nov 01 | View |
| Oct 11, 2016 | James R Neal | VP BUSINESS DEVELOPMENT | -2.50K | $0.45 | -$1.12K | SELL | -0.58% | 427.03K | Oct 07 | View |
| Mar 22, 2016 | Thomas M Burns | VP, FINANCE & CHIEF FINANCIAL | -19.25K | $0.78 | -$15.10K | SELL | -8.92% | 196.56K | Mar 22 | View |
| Mar 22, 2016 | James R Neal | VP BUSINESS DEVELOPMENT | -19.81K | $0.78 | -$15.55K | SELL | -4.46% | 424.53K | Mar 22 | View |
| Mar 22, 2016 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | -12.05K | $0.78 | -$18.99K | SELL | -3.42% | 340.02K | Mar 18 - Mar 22 | View |
| Mar 22, 2016 | Patrick J. Scannon MD, PhD | EXEC. VP & CSO | -5.29K | $0.78 | -$11.60K | SELL | -2.22% | 233.00K | Mar 18 - Mar 22 | View |
| Mar 22, 2016 | John Varian | CEO | -44.12K | $0.78 | -$63.58K | SELL | -3.74% | 1.14M | Mar 18 - Mar 22 | View |
| Feb 03, 2016 | Patrick Scannon MD, PhD | EXEC. VP & CSO | -8.00K | $1.01 | -$8.08K | SELL | -7.53% | 98.28K | Feb 01 | View |
| Dec 30, 2015 | Patrick J. Scannon MD, PhD. | EXEC. VP & CSO | -8.00K | $1.37 | -$10.94K | SELL | -7.00% | 106.28K | Dec 28 | View |
| Nov 25, 2015 | Patrick J Scannon MD, PhD | EXEC. VP & CSO | -8.00K | $1.35 | -$10.80K | SELL | -6.54% | 114.28K | Nov 23 | View |
| Oct 28, 2015 | Patrick J Scannon MD, PhD | EXEC. VP & CSO | -8.00K | $1.04 | -$8.36K | SELL | -6.14% | 122.28K | Oct 26 | View |
| Jul 23, 2015 | BAKER BROS ADVISORS LP LPBaker Brothers Life Sciences LP LPBaker Bros Advisors GP LLCFELIX BAKERJULIAN BAKER | — | -11.00M | $1.09 | -$12.02M | SELL | -99.18% | 90.54K | Jul 22 | View |
| Jul 17, 2015 | John Varian | CEO | 0.00 | $2.86 | -$32.47K | SELL-OPTIONS | 0.00% | 570.95K | Jul 15 | View |
| Jul 17, 2015 | Paul Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.82 | -$7.79K | SELL-OPTIONS | 0.00% | 129.23K | Jul 15 | View |
| Jul 10, 2015 | Paul Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.80 | -$50.47K | SELL-OPTIONS | 0.00% | 129.23K | Jul 09 - Jul 10 | View |
| Jun 17, 2015 | John Varian | CEO | 0.00 | $2.44 | -$23.96K | SELL-OPTIONS | 0.00% | 570.95K | Jun 15 | View |
| Jun 01, 2015 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 2.88K | $3.60 | -$6.44K | SELL-OPTIONS | 2.28% | 129.23K | May 28 | View |
| May 19, 2015 | John Varian | CEO | 0.00 | $2.29 | -$21.00K | SELL-OPTIONS | 0.00% | 570.95K | May 15 | View |
| Apr 15, 2015 | John Varian | CEO | 0.00 | $2.55 | -$26.21K | SELL-OPTIONS | 0.00% | 570.95K | Apr 15 | View |
| Mar 23, 2015 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | -32.74K | $3.94 | -$128.88K | SELL | -20.58% | 126.35K | Mar 23 | View |
| Mar 17, 2015 | John Varian | CEO | 0.00 | $2.48 | -$24.82K | SELL-OPTIONS | 0.00% | 578.92K | Mar 16 | View |
| Feb 19, 2015 | Jon Varian | CEO | 0.00 | $2.38 | -$22.79K | SELL-OPTIONS | 0.00% | 385.72K | Feb 17 | View |
| Feb 03, 2015 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | -5.00K | $3.52 | -$17.62K | SELL | -5.85% | 80.40K | Feb 02 | View |
| Jan 16, 2015 | John Varian | CEO | 0.00 | $2.35 | -$22.18K | SELL-OPTIONS | 0.00% | 382.72K | Jan 15 | View |
| Jan 06, 2015 | BAKER BROS ADVISORS LP LPBaker Brothers Life Sciences LP LPBaker Bros Advisors GP LLCFELIX BAKERJULIAN BAKER | DIRECTOR | -2.22M | $3.81 | -$8.44M | SELL | -86.52% | 345.07K | Jan 02 - Jan 06 | View |
| Jan 05, 2015 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | -5.00K | $3.55 | -$17.76K | SELL | -5.53% | 85.40K | Jan 02 | View |
| Dec 30, 2014 | BAKER BROS ADVISORS LP LPBaker Brothers Life Sciences LP LPBaker Bros Advisors GP LLCFELIX BAKERJULIAN BAKER | DIRECTOR | -744.00K | $3.67 | -$2.73M | SELL | -65.46% | 392.62K | Dec 26 - Dec 30 | View |
| Dec 19, 2014 | BAKER BROS ADVISORS LP LPBaker Brothers Life Sciences LP LPBaker Bros Advisors GP LLCFELIX BAKERJULIAN BAKER | DIRECTOR | -1.61M | $4.26 | -$6.84M | SELL | -79.71% | 408.60K | Dec 17 - Dec 19 | View |
| Dec 16, 2014 | BAKER BROS ADVISORS LP LPBaker Brothers Life Sciences LP LPBaker Bros Advisors GP LLCFELIX BAKERJULIAN BAKER | DIRECTOR | -1.03M | $4.46 | -$4.61M | SELL | -70.00% | 443.10K | Dec 12 - Dec 16 | View |
| Dec 16, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.83 | -$2.54K | SELL-OPTIONS | 0.00% | 77.33K | Dec 15 | View |
| Dec 16, 2014 | John Varian | CEO | 0.00 | $2.87 | -$32.53K | SELL-OPTIONS | 0.00% | 382.72K | Dec 15 | View |
| Dec 10, 2014 | BAKER BROS ADVISORS LP LPBaker Brothers Life Sciences LP LPBaker Bros Advisors GP LLCFELIX BAKERJULIAN BAKER | DIRECTOR | -392.35K | $4.62 | -$1.81M | SELL | -45.75% | 465.33K | Dec 09 | View |
| Dec 04, 2014 | BAKER BROS ADVISORS LP LPBaker Brothers Life Sciences LP LPBaker Bros Advisors GP LLCFELIX BAKERJULIAN BAKER | DIRECTOR | -2.37M | $4.79 | -$11.36M | SELL | -83.35% | 473.76K | Dec 02 - Dec 04 | View |
| Dec 01, 2014 | James R Neal | — | -1.68K | $5.67 | -$9.51K | SELL | -1.19% | 139.23K | Nov 26 | View |
| Dec 01, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | -5.00K | $5.51 | -$27.57K | SELL | -5.24% | 90.40K | Dec 01 | View |
| Nov 24, 2014 | James R Neal | VP BUSINESS DEVELOPMENT | -1.03K | $5.03 | -$5.19K | SELL | -0.73% | 140.91K | Nov 24 | View |
| Nov 21, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.79 | -$7.55K | SELL-OPTIONS | 0.00% | 77.33K | Nov 20 | View |
| Nov 17, 2014 | Fred Kurland | CFO & VP FINANCE | 13.82K | $3.89 | -$34.15K | SELL-OPTIONS | 18.07% | 90.34K | Nov 13 | View |
| Nov 17, 2014 | Patrick J. Scannon Ph.D., M.D. | EXEC. VP & CSO | 14.41K | $3.89 | -$32.09K | SELL-OPTIONS | 17.79% | 95.40K | Nov 13 | View |
| Nov 17, 2014 | John Varian | CEO | 41.82K | $3.89 | -$229.04K | SELL-OPTIONS | 12.27% | 382.72K | Nov 13 | View |
| Nov 17, 2014 | James R Neal | VP BUSINESS DEVELOPMENT | -4.39K | $3.89 | -$17.08K | SELL | -3.00% | 141.94K | Nov 13 | View |
| Nov 03, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | -5.00K | $4.33 | -$21.66K | SELL | -5.81% | 80.99K | Nov 03 | View |
| Oct 29, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.80 | -$7.63K | SELL-OPTIONS | 0.00% | 77.33K | Oct 28 | View |
| Oct 15, 2014 | John Varian | CEO | 0.00 | $2.55 | -$26.29K | SELL-OPTIONS | 0.00% | 340.90K | Oct 15 | View |
| Oct 01, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | -5.00K | $4.09 | -$20.45K | SELL | -5.49% | 85.99K | Oct 01 | View |
| Sep 16, 2014 | John Varian | CEO | 0.00 | $2.90 | -$33.18K | SELL-OPTIONS | 0.00% | 340.90K | Sep 15 | View |
| Sep 16, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.81 | -$7.74K | SELL-OPTIONS | 0.00% | 77.33K | Sep 15 | View |
| Sep 08, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.80 | -$15.24K | SELL-OPTIONS | 0.00% | 77.33K | Sep 04 | View |
| Sep 03, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | -5.00K | $4.31 | -$21.55K | SELL | -5.21% | 90.99K | Sep 02 | View |
| Aug 19, 2014 | Fred Kurland | CFO & VP FINANCE | 8.66K | $4.31 | -$44.78K | SELL-OPTIONS | 12.77% | 76.52K | Aug 14 - Aug 15 | View |
| Aug 19, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $4.34 | -$116.09K | SELL-OPTIONS | 0.00% | 77.33K | Aug 14 - Aug 18 | View |
| Aug 18, 2014 | James R Neal | VP BUSINESS DEVELOPMENT | -6.58K | $4.61 | -$30.32K | SELL | -4.31% | 146.33K | Aug 15 | View |
| Aug 18, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | 10.39K | $4.31 | -$25.28K | SELL-OPTIONS | 12.14% | 95.99K | Aug 14 - Aug 15 | View |
| Aug 18, 2014 | John Varian | CEO | 39.75K | $2.77 | -$266.63K | SELL-OPTIONS | 13.20% | 340.90K | Aug 14 - Aug 15 | View |
| Aug 04, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | -5.00K | $3.83 | -$19.16K | SELL | -5.52% | 85.60K | Aug 01 | View |
| Jul 16, 2014 | John Varian | CEO | 0.00 | $2.63 | -$27.89K | SELL-OPTIONS | 0.00% | 301.15K | Jul 15 | View |
| Jul 02, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | -5.00K | $4.68 | -$23.41K | SELL | -5.23% | 90.60K | Jul 01 | View |
| Jun 18, 2014 | John Varian | CEO | 0.00 | $2.89 | -$33.01K | SELL-OPTIONS | 0.00% | 301.15K | Jun 16 | View |
| Jun 18, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | -11.58K | $4.54 | -$52.60K | SELL | -13.02% | 77.33K | Jun 16 | View |
| May 29, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 2.88K | $4.22 | -$7.53K | SELL-OPTIONS | 3.35% | 88.91K | May 28 | View |
| May 15, 2014 | John Varian | CEO | 0.00 | $2.40 | -$23.11K | SELL-OPTIONS | 0.00% | 301.15K | May 15 | View |
| May 15, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | -10.00K | $3.84 | -$38.40K | SELL | -10.41% | 86.03K | May 13 | View |
| Apr 17, 2014 | John Varian | CEO | 0.00 | $2.65 | -$28.25K | SELL-OPTIONS | 0.00% | 301.15K | Apr 15 | View |
| Mar 20, 2014 | Fred Kurland | CFO & VP FINANCE | 4.96K | $6.32 | -$37.36K | SELL-OPTIONS | 7.89% | 67.85K | Mar 18 | View |
| Mar 20, 2014 | John Varian | CEO | 15.58K | $6.32 | -$134.71K | SELL-OPTIONS | 5.46% | 301.15K | Mar 18 | View |
| Mar 20, 2014 | James R Neal | VP BUSINESS DEVELOPMENT | -2.67K | $6.32 | -$16.87K | SELL | -1.72% | 152.91K | Mar 18 | View |
| Mar 20, 2014 | Thomas Klein | CHIEF COMMERCIAL OFFICER | 49.70K | $6.32 | -$195.57K | SELL-OPTIONS | 110.19% | 94.81K | Mar 18 | View |
| Mar 20, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | 6.08K | $6.32 | -$21.59K | SELL-OPTIONS | 6.79% | 95.60K | Mar 18 | View |
| Mar 20, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 18.70K | $4.68 | -$93.18K | SELL-OPTIONS | 24.18% | 96.03K | Mar 18 | View |
| Mar 18, 2014 | John Varian | CEO | 0.00 | $3.63 | -$47.89K | SELL-OPTIONS | 0.00% | 285.57K | Mar 17 | View |
| Feb 19, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $5.29 | -$27.03K | SELL-OPTIONS | 0.00% | 8.54K | Feb 18 | View |
| Feb 19, 2014 | John Varian | CEO | 0.00 | $4.39 | -$63.08K | SELL-OPTIONS | 0.00% | 164.28K | Feb 18 | View |
| Jan 23, 2014 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | -306.00 | $5.65 | -$32.30K | SELL | -3.85% | 7.65K | Jan 21 | View |
| Jan 17, 2014 | John Varian | CEO | 0.00 | $4.76 | -$70.39K | SELL-OPTIONS | 0.00% | 162.54K | Jan 15 | View |
| Jan 10, 2014 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | 0.00 | $4.85 | -$126.24K | SELL-OPTIONS | 0.00% | 46.07K | Jan 09 | View |
| Dec 18, 2013 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $4.35 | -$15.75K | SELL-OPTIONS | 0.00% | 7.96K | Dec 18 | View |
| Dec 18, 2013 | John Varian | CEO | 0.00 | $3.34 | -$41.97K | SELL-OPTIONS | 0.00% | 162.54K | Dec 16 | View |
| Dec 03, 2013 | Patrick J. Scannon M.D., Ph.D. | EXEC. VP & CSO | 0.00 | $3.85 | -$86.20K | SELL-OPTIONS | 0.00% | 46.07K | Dec 02 | View |
| Dec 02, 2013 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.79 | -$7.04K | SELL-OPTIONS | 0.00% | 7.96K | Nov 27 | View |
| Nov 19, 2013 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.22 | -$2.24K | SELL-OPTIONS | 0.00% | 7.96K | Nov 18 | View |
| Nov 15, 2013 | John Varian | CEO | 45.73K | $2.59 | -$243.87K | SELL-OPTIONS | 39.15% | 162.54K | Nov 13 - Nov 15 | View |
| Nov 15, 2013 | Patrick J. Scannon MD, PhD | EXEC. VP & CSO | 14.31K | $3.91 | -$32.66K | SELL-OPTIONS | 45.04% | 46.07K | Nov 13 | View |
| Nov 15, 2013 | Fred Kurland | CFO & VP FINANCE | 10.27K | $3.91 | -$48.24K | SELL-OPTIONS | 61.03% | 27.09K | Nov 13 | View |
| Oct 21, 2013 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.53 | -$1.75K | SELL-OPTIONS | 0.00% | 13.21K | Oct 18 | View |
| Oct 16, 2013 | John Varian | DIRECTOR AND CEO | 0.00 | $2.92 | -$33.55K | SELL-OPTIONS | 0.00% | 116.80K | Oct 15 | View |
| Sep 19, 2013 | PAUL RUBIN | SR. VP CLINICAL DEV. & CMO | -6.00K | $4.53 | -$27.19K | SELL | -32.00% | 12.75K | Sep 18 | View |
| Sep 17, 2013 | John Varian | DIRECTOR AND CEO | 0.00 | $2.91 | -$33.46K | SELL-OPTIONS | 0.00% | 116.80K | Sep 16 | View |
| Aug 19, 2013 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | -6.00K | $3.74 | -$22.42K | SELL | -24.24% | 18.75K | Aug 19 | View |
| Aug 16, 2013 | John Varian | DIRECTOR AND CEO | 42.93K | $2.56 | -$226.23K | SELL-OPTIONS | 58.11% | 116.80K | Aug 14 - Aug 15 | View |
| Aug 16, 2013 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 16.23K | $3.86 | -$40.62K | SELL-OPTIONS | 190.40% | 24.75K | Aug 14 | View |
| Aug 16, 2013 | Patrick J. Scannon | EXEC. VP & CSO | 10.26K | $3.86 | -$23.17K | SELL-OPTIONS | 47.73% | 31.76K | Aug 14 | View |
| Aug 16, 2013 | Fred Kurland | CFO & VP FINANCE | -1.67K | $3.86 | -$28.95K | SELL | -9.01% | 16.82K | Aug 14 - Aug 15 | View |
| Jul 19, 2013 | Paul D Rubin | SR. VP CLINICAL DEV. & CMO | 0.00 | $3.72 | -$11.86K | SELL-OPTIONS | 0.00% | 8.52K | Jul 18 | View |
| Jul 17, 2013 | John Varian | DIRECTOR AND CEO | 0.00 | $3.02 | -$35.67K | SELL-OPTIONS | 0.00% | 73.88K | Jul 15 | View |
| Jun 18, 2013 | Paul Rubin | SR. VP CLINICAL DEV. & CMO | -2.87K | $2.36 | $7.39K | SELL | -26.51% | 7.96K | Jun 18 | View |
| Jun 18, 2013 | John Varian | DIRECTOR AND CEO | 0.00 | $1.24 | $12.40K | SELL-OPTIONS | 0.00% | 73.88K | Jun 17 | View |
| Jun 12, 2013 | Patrick J. Scannon | EXEC. VP & CSO | 0.00 | $1.69 | $16.90K | SELL-OPTIONS | 0.00% | 21.50K | Jun 11 | View |
| May 29, 2013 | Paul Rubin | SR. VP CLINICAL DEV. & CMO | 2.87K | $4.16 | -$7.48K | SELL-OPTIONS | 36.07% | 10.83K | May 28 - May 29 | View |
| May 21, 2013 | Paul Rubin | SR. VP CLINICAL DEV. & CMO | -5.21K | $3.26 | -$1.41K | SELL | -39.59% | 7.96K | May 20 | View |
| May 15, 2013 | Patrick J. Scannon | EXEC. VP & CSO | 0.00 | $1.69 | $16.90K | SELL-OPTIONS | 0.00% | 21.50K | May 14 | View |
| May 15, 2013 | John Varian | DIRECTOR AND CEO | 0.00 | $1.24 | $12.40K | SELL-OPTIONS | 0.00% | 73.88K | May 15 | View |
| Apr 19, 2013 | Paul Rubin | SR. VP CLINICAL DEV. & CMO | -6.00K | $0.00 | $0.00 | SELL | -31.30% | 13.17K | Apr 18 | View |
| Mar 27, 2013 | Paul Rubin | SR. VP CLINICAL DEV. & CMO | 11.21K | $3.29 | -$23.00K | SELL-OPTIONS | 173.66% | 17.67K | Mar 18 - Mar 19 | View |
| Nov 15, 2012 | John Varian | DIRECTOR AND CEO | 60.08K | $2.56 | -$103.81K | SELL-OPTIONS | 643.11% | 69.42K | Nov 13 - Nov 14 | View |
| Nov 15, 2012 | Patrick J. Scannon MD, PhD | EXECUTIVE VICE PRESIDENT | 13.88K | $2.56 | -$22.44K | SELL-OPTIONS | 182.13% | 21.50K | Nov 13 - Nov 14 | View |
| Nov 15, 2012 | Fred Kurland | CFO & VP FINANCE | 13.48K | $2.56 | -$23.31K | SELL-OPTIONS | 269.70% | 18.48K | Nov 13 - Nov 14 | View |
| Oct 31, 2012 | JULIAN BAKERBAKER BROS ADVISORS LLC LPBaker Brothers Life Sciences LP LPFELIX BAKER | DIRECTOR | 4.72M | $3.00 | $14.17M | BUY | ∞ | 480.64K | Oct 29 | View |
| Nov 16, 2011 | W. Denman Van Ness | DIRECTOR | -698.00 | $1.60 | -$1.12K | SELL | -21.10% | 2.61K | Nov 11 | View |
| Mar 28, 2011 | Fred Kurland | CFO & VP FINANCE | 5.00K | $3.26 | $16.32K | BUY | 146.33% | 8.42K | Mar 25 | View |
| Aug 17, 2005 | J. David Boyle II | VP, FINANCE, AND CFO | 5.00K | $1.44 | $7.20K | BUY | ∞ | 5.00K | Aug 17 | View |
| May 12, 2005 | Clarence L Dellio | SR VP, OPERATIONS AND COO | -10.97K | $1.41 | -$15.49K | SELL | -8.55% | 117.43K | May 11 | View |
| Mar 31, 2005 | Christopher J Margolin | VP, GENERAL COUNSEL & SEC'Y | -53.70K | $1.03 | -$55.47K | SELL | -42.99% | 71.20K | Mar 30 | View |
| Sep 20, 2004 | Clarence L Dellio | SR VP, OPERATIONS AND COO | -4.29K | $2.51 | -$10.78K | SELL | -3.71% | 111.59K | Sep 17 | View |
| Jul 01, 2004 | Clarence Dellio | SR VP, OPERATIONS AND COO | -4.00K | $4.75 | -$19.00K | SELL | -3.34% | 115.88K | Jun 30 | View |
| May 24, 2004 | James G Andress | DIRECTOR | 2.00K | $3.99 | $7.98K | BUY | ∞ | 2.00K | May 21 | View |
| Apr 14, 2004 | Steven C Mendell | DIRECTOR | 0.00 | $4.13 | -$1.50K | SELL-OPTIONS | 0.00% | 40.63K | Apr 13 | View |
| Apr 14, 2004 | Patrick J. Scannon MD, PhD | CSMO | 0.00 | $3.74 | -$185.53K | SELL-OPTIONS | 0.00% | 87.27K | Apr 13 | View |
| Mar 25, 2004 | Peter B Davis | VP, FINANCE & CFO | 5.00K | $4.79 | $23.93K | BUY | 4.99% | 105.21K | Mar 25 | View |
| Jan 12, 2004 | Christopher J Margolin | VP, GENERAL COUNSEL & SEC'Y | 35.00K | $5.03 | -$114.92K | SELL-OPTIONS | 60.40% | 92.95K | Jan 09 | View |
| Jan 12, 2004 | Clarence L Dellio | SR VP, OPERATIONS AND COO | -15.97K | $7.49 | -$119.61K | SELL | -12.27% | 114.15K | Jan 09 | View |
| Dec 23, 2003 | Patrick J. Scannon MD, PhD | CSMO | 0.00 | $4.55 | -$417.91K | SELL-OPTIONS | 0.00% | 85.11K | Dec 23 | View |
FAQ
Q
Is insider trading legal?
A
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
Q
What are some examples of market manipulation?
A
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.
XOMA Insider Trading News
People Also Watch
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved